Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Phathom Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

FLORHAM PARK, N.J., JULY 30, 2026 (GLOBE NEWSWIRE) -- PHATHOM PHARMACEUTICALS, INC. (NASDAQ: PHAT), A BIOPHARMACEUTICAL COMPANY FOCUSED ON COMMERCIALIZING AND DEVELOPING NOVEL TREATMENTS FOR GASTROINTESTINAL (GI) DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026, AND PROVIDED A BUSINESS UPDATE.

PHATHOM PHARMACEUTICALS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

MANAGEMENT TO HOST CONFERENCE CALL ON THURSDAY, JULY 30, 2026, AT 8:00 AM EDT MANAGEMENT TO HOST CONFERENCE CALL ON THURSDAY, JULY 30, 2026, AT 8:00 AM EDT

PHATHOM PHARMACEUTICALS TO REPORT SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON THURSDAY, JULY 30, 2026

THIS TRIAL IS THE FIRST LARGE, PLACEBO-CONTROLLED CLINICAL TRIAL OF AN ACID SUPPRESSION TREATMENT IN EOE TOPLINE RESULTS FOR THE DOUBLE-BLIND 12-WEEK TREATMENT PORTION OF THE STUDY ARE EXPECTED IN Q4 OF 2026 FLORHAM PARK, N.J., JUNE 23, 2026 (GLOBE NEWSWIRE) -- PHATHOM PHARMACEUTICALS, INC. (NASDAQ: PHAT), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING NOVEL TREATMENTS FOR GASTROINTESTINAL (GI) DISEASES, TODAY ANNOUNCED IT HAS COMPLETED ENROLLMENT IN ITS PHASE 2 PHALCON-EOE-201 CLINICAL TRIAL EVALUATING VOQUEZNA (VONOPRAZAN) TABLETS AS AN INVESTIGATIONAL TREATMENT FOR EOSINOPHILIC ESOPHAGITIS (EOE) IN ADULTS.

PHATHOM PHARMACEUTICALS COMPLETES PATIENT ENROLLMENT AHEAD OF SCHEDULE IN PHASE 2 PHALCON-EOE-201 STUDY OF VOQUEZNA (VONOPRAZAN) IN EOSINOPHILIC ESOPHAGITIS (EOE)

FLORHAM PARK, N.J., MAY 22, 2026 (GLOBE NEWSWIRE) -- PHATHOM PHARMACEUTICALS, INC. (NASDAQ: PHAT), A BIOPHARMACEUTICAL COMPANY FOCUSED ON COMMERCIALIZING AND DEVELOPING NOVEL TREATMENTS FOR GASTROINTESTINAL (GI) DISEASES, ANNOUNCED TODAY THAT MEMBERS OF ITS MANAGEMENT TEAM ARE SCHEDULED TO PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES IN MAY AND JUNE:

PHATHOM PHARMACEUTICALS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

FLORHAM PARK, N.J., MAY 20, 2026 (GLOBE NEWSWIRE) -- PHATHOM PHARMACEUTICALS, INC. (NASDAQ: PHAT), A BIOPHARMACEUTICAL COMPANY FOCUSED ON COMMERCIALIZING AND DEVELOPING NOVEL TREATMENTS FOR GASTROINTESTINAL (GI) DISEASES, TODAY HIGHLIGHTED THE GROWING BODY OF CLINICAL AND SCIENTIFIC RESEARCH ON VONOPRAZAN, THE ACTIVE INGREDIENT IN VOQUEZNA (VONOPRAZAN), AT DIGESTIVE DISEASE WEEK (DDW) 2026, HELD MAY 25, 2026 IN CHICAGO, ILLINOIS. PHATHOM PRESENTED THREE POSTERS AT THE MEETING, INCLUDING A PHATHOM-SPONSORED ANALYSIS FROM THE PHASE 3 PHALCON-NERD-301 STUDY THAT WAS RECOGNIZED BY DDW AS A POSTER OF DISTINCTION, A DESIGNATION RESERVED FOR ABSTRACTS OF NOTABLE SCIENTIFIC MERIT. VONOPRAZAN WAS ALSO THE SUBJECT OF 28 ADDITIONAL INDEPENDENT, INVESTIGATOR-INITIATED ABSTRACTS ACROSS GASTROESOPHAGEAL REFLUX DISEASE (GERD), HELICOBACTER PYLORI (H. PYLORI) ERADICATION, LONG-TERM SAFETY, AND POST ENDOSCOPIC PROCEDURAL CARE, REFLECTING THE GROWING SCIENTIFIC INTEREST IN VONOPRAZAN AND THE POTASSIUM-COMPETITIVE ACID BLOCKER (PCAB) CLASS IN GI MEDICINE.

PHATHOM PHARMACEUTICALS HIGHLIGHTS BREADTH OF INDEPENDENT VONOPRAZAN RESEARCH AT DIGESTIVE DISEASE WEEK 2026 ANNUAL MEETING

FLORHAM PARK, N.J., MAY 01, 2026 (GLOBE NEWSWIRE) -- PHATHOM PHARMACEUTICALS, INC. (NASDAQ: PHAT), A BIOPHARMACEUTICAL COMPANY FOCUSED ON COMMERCIALIZING AND DEVELOPING NOVEL TREATMENTS FOR GASTROINTESTINAL (GI) DISEASES, TODAY ANNOUNCED ITS PARTICIPATION IN THE DIGESTIVE DISEASE WEEK (DDW) 2026 ANNUAL MEETING, BEING HELD MAY 25 IN CHICAGO, ILLINOIS.

PHATHOM PHARMACEUTICALS TO HIGHLIGHT VOQUEZNA (VONOPRAZAN) AT DDW 2026 ANNUAL MEETING

FLORHAM PARK, N.J., APRIL 30, 2026 (GLOBE NEWSWIRE) -- PHATHOM PHARMACEUTICALS, INC. (NASDAQ: PHAT), A BIOPHARMACEUTICAL COMPANY FOCUSED ON COMMERCIALIZING AND DEVELOPING NOVEL TREATMENTS FOR GASTROINTESTINAL (GI) DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026, AND PROVIDED A BUSINESS UPDATE.

PHATHOM PHARMACEUTICALS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

MANAGEMENT TO HOST CONFERENCE CALL ON THURSDAY, APRIL 30, 2026, AT 8:00 AM EDT FLORHAM PARK, N.J., APRIL 20, 2026 (GLOBE NEWSWIRE) -- PHATHOM PHARMACEUTICALS, INC. (NASDAQ: PHAT), A BIOPHARMACEUTICAL COMPANY FOCUSED ON COMMERCIALIZING AND DEVELOPING NOVEL TREATMENTS FOR GASTROINTESTINAL (GI) DISEASES, TODAY ANNOUNCED THAT IT WILL HOST A LIVE WEBCAST AT 8:00 AM EDT ON THURSDAY, APRIL 30, 2026, TO REPORT ITS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDE A BUSINESS UPDATE.

PHATHOM PHARMACEUTICALS TO REPORT FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON THURSDAY, APRIL 30, 2026

FLORHAM PARK, N.J., APRIL 06, 2026 (GLOBE NEWSWIRE) -- PHATHOM PHARMACEUTICALS, INC. (NASDAQ: PHAT), A BIOPHARMACEUTICAL COMPANY FOCUSED ON COMMERCIALIZING AND DEVELOPING NOVEL TREATMENTS FOR GASTROINTESTINAL (GI) DISEASES, ANNOUNCED TODAY THAT MEMBERS OF ITS MANAGEMENT TEAM ARE SCHEDULED TO PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES IN APRIL: RAYMOND JAMES2026 BIOTECH INNOVATION SYMPOSIUM IN NEW YORK, NY DATE: TUESDAY, APRIL 14, 2026 MANAGEMENT TO PARTICIPATE IN ONE-ON-ONE MEETINGS THROUGHOUT THE CONFERENCE 25TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE DATE: WEDNESDAY, APRIL 15, 2026FIRESIDE CHAT: 1:30 PM EDT MANAGEMENT TO PARTICIPATE IN ONE-ON-ONE MEETINGS THROUGHOUT THE CONFERENCE TO ACCESS THE LIVE WEBCAST AND ARCHIVED RECORDING OF THE EVENT, VISIT THE NEWS & EVENTS SECTION OF THE PHATHOM WEBSITE ATHTTPS://INVESTORS.PHATHOMPHARMA.COM/NEWS-EVENTS/EVENTS-AND-PRESENTATIONS.

OVER 1.1 MILLION TOTAL VOQUEZNA PRESCRIPTIONS FILLED TO DATE $57.6 MILLION IN Q4 NET REVENUES; $175.1 MILLION IN FY 2025 NET REVENUES, A 217% INCREASE FROM FY 2024 Q4 OPERATING EXPENSES OF $55.9 MILLION; NON-GAAP OPERATING EXPENSES OF $50.3 MILLION AND NET CASH USAGE OF APPROXIMATELY $5.2 MILLION, REFLECTING CONTINUED EXPENSE DISCIPLINE STRENGTHENED FINANCIAL POSITION THROUGH $130 MILLION EQUITY OFFERING AND MODIFICATION OF TERM DEBT PROVIDING FY 2026 GUIDANCE; OPERATING PROFITABILITY EXPECTED BEGINNING IN Q3 2026 AND FOR FY 2026 MANAGEMENT TO HOST CONFERENCE CALL TODAY, FEBRUARY 26, 2026, AT 8:00 A.M. EST FLORHAM PARK, N.J.

Phathom Pharmaceuticals, Inc.

PHAT

Price

Financial Reports

No items found.

Press Releases

Phathom Pharmaceuticals, Inc.

PHAT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

PHAT